GlaxoSmithKline PLC (LSE:GSK) - Share price


Stock Report

GlaxoSmithKline PLC GSK

Last Price
GBX1,450.60

Day Change
-5.80|-0.40%

As of 25/09/2020
11:53:10 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,456.40p
Day Range1,450.00 - 1,462.60
Mkt Cap73.07Bil
52-Wk Range1,328.19 - 1,857.00
Yield %5.36
ISINGB0009252882
Volume908,912
P/E11.24
P/S0.02
P/CF0.09

Share Price

Total Returns 24/09/2020

 Chg (%)  
More ...
GlaxoSmithKline PLC-4.26 
FTSE 100 TR GBP-4.52
 
Financials
201720182019
More ...
Income Statement
Turnover30,186.0030,821.0033,754.00
Operating Profit6,061.007,060.006,292.00
Net Profit2,169.004,046.005,268.00
Reported EPS31.0072.9092.60
Balance Sheet
Current Assets15,794.0016,274.0018,618.00
Non Current Assets40,474.0041,139.0060,201.00
Total Assets56,381.0058,066.0079,692.00
Current Liabilities26,569.0022,491.0024,050.00
Total Liabilities---
Total Equity3,489.003,672.0018,357.00
Cash Flow
Operating Cash Flow8,258.009,747.009,532.00
Net Change in Cash-905.00479.00826.00

Regulatory News

DateAuthor Headline
15/09/2020James Gard Top 20 FTSE Dividend Paying Stocks
UPDATED September 2020: WPP yielding above 5% again as it reinstates its dividend
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete
10/07/2019Emma Simon Dividend Shares to Fund My Retirement
Investor Views: Private investor Gurmit Dhendsa is running his own share portfolio rather than rely on a pension manager
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
10/09/2020PurchaseMs. Emma N. Walmsley1,520.358122.00
10/09/2020Transfer inMs. Emma N. Walmsley0.0080.00
11/08/2020Transfer inMs. Emma N. Walmsley0.0080.00
11/08/2020PurchaseMs. Emma N. Walmsley1,597.858128.00

Company Profile

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Sector

Drug Manufacturers - General

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 28/10/2020

Third Quarter Results
Ratios
Comp
More ...
PER (E)11.08
Div Yld (E)5.43
PEG (E)7.41
ROCE12.77
Op Mrgn0.19
EPS Grwth-0.19
Dividends
PreviousLatest
More ...
Record Date15/05/2014/08/20
Ex-Div14/05/2013/08/20
Paid09/07/2008/10/20
Amnt19.0019.00
Directors
More ...
Non-Executive DirectorMs. Lynn Laverty Elsenhans
Executive Director, Chief Scientific Officer and President, RandDDr. Hal V Barron
Non-Executive DirectorMs. Judy C. Lewent
Non-Executive DirectorDr. Laurie H. Glimcher, M.D.
Non-Executive Director, ChairmanMr. Jonathan Richard Symonds CBE
Non-Executive Director, Senior Independent DirectorMr. Manvinder Singh Banga
Non-Executive DirectorMr. Urs Rohner
Non-Executive DirectorDr. Vivienne Cox, CBE
Non-Executive DirectorMr. Charles A. Bancroft
Company SecretaryMrs. Victoria Anne Whyte
Executive Director, Chief Financial OfficerMr. Iain J Mackay
Executive Director, Chief Executive OfficerMs. Emma N. Walmsley
Non-Executive DirectorDr. Jesse Goodman
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.